The content on this site is intended for healthcare professionals only
Prof Helena Earl speaks to ecancer about the reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer.
Initially, she explains that this systematic review identified five NI RCTs, and trial groups agreed a meta-analysis collaboration.
Prof Earl then discusses the methodology and results of this study. She says that this study proved that six months trastuzumab is non-inferior to 12months, although nine weeks is not.
She concludes by discussing the impact these results could have on the future of treating breast cancer.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
ASCO 2024: Lung cancer highlights
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC
OncoAlert round up July 28th to August 3rd, 2023
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
Breast cancer in elderly patients: a clinicopathological review of a Nigerian database
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC
